Is NAD+ FDA Approved? The Regulatory Record

September 8, 2026
Juan Montes

No. There is no FDA approved NAD+ drug product in the United States, by any route, for any indication.

That answer is accurate and, on its own, misleading. “Not FDA approved” describes several very different regulatory positions, and NAD sits in a notably better one than most of what it is sold alongside. Here is the actual record.

This page is general information, not medical advice. Whether NAD+ is appropriate for you is a decision for a licensed clinician who has reviewed your health history.

NAD is in FDA 503A Category 1

FDA maintains a list of bulk drug substances nominated for use in compounding under section 503A, sorted into three categories:

Category	What FDA has said	Practical effect
Category 1	Sufficient supporting information and no identified safety risk of the kind that triggers enforcement. FDA does not intend to take action against a compounder using it, when the other 503A conditions are met	A licensed pharmacy may compound it on a valid prescription
Category 2	Safety risks identified. FDA would consider taking action	Compounding it invites enforcement
Category 3	Not enough information nominated to evaluate	Also not eligible for the Category 1 policy

NAD is in Category 1. So is glutathione. That puts both on the more permissive side of the list.

This is a real distinction and it is worth understanding, because a great deal of what is marketed in the longevity and peptide space does not have this status. Several widely promoted compounds sit in Category 2, and others were never successfully nominated at all. We keep a running record on the FDA compounding status tracker. The parallel answer for glutathione is at is glutathione FDA approved.

What Category 1 does not mean

This is where marketing tends to overreach, so it is worth being blunt.

It is not a finding that NAD+ works. FDA has not evaluated effectiveness for any indication, because no one has submitted a product for approval.
It is not a safety approval. It means no safety risk was identified that would trigger enforcement against compounders. That is a lower bar than an approved label.
It says nothing about dose, schedule or duration. There is no approved labelling to derive those from, which is exactly why NAD+ dosage is more uncertain than most people assume.
It does not cover every form. Category status attaches to the substance, and how a given product is prepared and administered is a separate question.

NAD+ versus NAD precursors sold as supplements

A separate source of confusion. Compounds marketed as NAD precursors are sold as dietary supplements, which is a different regulatory route entirely: no drug approval, no premarket review of effectiveness, and manufacturing standards that are not the ones applied to injectables. Some precursors have had contested regulatory histories of their own.

The practical point for a patient is simple. A supplement labelled for oral use is not an injectable drug and should never be treated as one. FDA published a reminder in August 2026 aimed squarely at compounders using supplement grade material for injectables, after patients were hospitalised. That alert concerned glutathione, and the principle applies to anything given by injection. The detail is in glutathione side effects and the sourcing question.

So is compounded NAD+ legal?

Compounded NAD+ prepared by a licensed pharmacy for an individual patient, on a valid prescription from a clinician licensed in that patient’s state, is operating within the 503A pathway that Category 1 status speaks to. Buying vials online without a prescription is not the same thing, and neither is injecting a product labelled as a supplement.

This describes the regulatory landscape. It is not legal advice.

The summary

Not FDA approved. No approved NAD+ product exists.
In Category 1 of the 503A list, which is the most permissive category and better than much of the longevity market.
Category 1 is a compounding policy, not an efficacy finding.
Route, sourcing and the prescribing relationship all still matter.

For the wider picture see the NAD+ therapy guide, and for what is reported clinically see NAD+ side effects.

Sources

Every quotation attributed to the FDA on this page is taken from the documents below. Follow the links and check them.

FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
FDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables

Last reviewed 9 September 2026. Regulatory status in compounding changes. If you are reading this well after that date, check the FDA sources directly rather than relying on this page.

Longevity plans from PrescribedRX

PrescribedRX prescribes longevity treatments through clinicians licensed in your state:

Glutathione Injection. Administered by injection after a provider consultation.
Glutathione Nasal Spray. A nasal alternative.
NAD+ Injections. On a schedule set by your provider.
NAD+ Nasal Spray. A nasal alternative.
Sermorelin Injections. By prescription after consultation.

Every plan and its current price is on the plans page and the pricing page.

These are compounded preparations. Compounded drugs are not reviewed or approved by the FDA for safety or effectiveness, and treatment outcomes are not guaranteed.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.